Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer With and Without T790M Mutations

Míreanna Comhchosúla

• Acquired Resistance of EGFR-Mutant Lung Adenocarcinomas to Afatinib plus Cetuximab Is Associated with Activation of mTORC1
  le: Valentina Pirazzoli, et al.
  Foilsithe: (2014-05-01)
• Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1
  le: Pirazzoli, Valentina, et al.
  Foilsithe: (2014)
• Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo
  le: Kudo, Kenichiro, et al.
  Foilsithe: (2017)
• Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non–Small-Cell Lung Cancer: Final Results From SWOG S1403
  le: Goldberg, Sarah B., et al.
  Foilsithe: (2020)
• HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR mutant lung cancers that lack the second-site EGFR T790M mutation
  le: Takezawa, Ken, et al.
  Foilsithe: (2012)